BRIEF-Tenaya Therapeutics says early trial shows promise for gene therapy in rare heart condition

Reuters12-12

BRIEF-Tenaya <a href="https://laohu8.com/S/LENZ">Therapeutics</a> says early trial shows promise for gene therapy in rare heart condition

Dec 11 (Reuters) - Tenaya Therapeutics Inc TNYA.O:

TENAYA THERAPEUTICS REPORTS POSITIVE INTERIM DATA FROM COHORT 1 OF RIDGE™-1 PHASE 1B/2 CLINICAL TRIAL OF TN-401 GENE THERAPY FOR ADULTS WITH PKP2-ASSOCIATED ARVC
TENAYA THERAPEUTICS INC - TN-401 WELL TOLERATED AT 3E13 VG/KG DOSE
TENAYA THERAPEUTICS INC - MEANINGFUL REDUCTIONS IN ARRHYTHMIA BURDEN OBSERVED IN FIRST TWO PATIENTS WITH MORE THAN SIX MONTHS OF FOLLOW-UP
TENAYA THERAPEUTICS INC: ROBUST TRANSDUCTION AND DEMONSTRATED INCREASES IN PKP2 PROTEIN LEVELS IN FIRST TWO PATIENTS AT WEEK 8

Source text: ID:nGNX8sWwFl

Further company coverage: TNYA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590491445?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 05:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590491445","market":"nz","top_or_hot":-1,"title":"BRIEF-Tenaya Therapeutics says early trial shows promise for gene therapy in rare heart condition","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Tenaya <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> says early trial shows promise for gene therapy in rare heart condition </title></head><body><p><span>Dec 11 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/TNYA\">Tenaya Therapeutics Inc</a> <span>TNYA.O</span>:</p><ul><li><p>TENAYA THERAPEUTICS REPORTS POSITIVE INTERIM DATA FROM <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> 1 OF RIDGE™-1 PHASE 1B/2 CLINICAL TRIAL OF TN-401 GENE THERAPY FOR ADULTS WITH PKP2-ASSOCIATED ARVC</p></li><li><p>TENAYA THERAPEUTICS INC - TN-401 WELL TOLERATED AT 3E13 VG/KG DOSE</p></li><li><p>TENAYA THERAPEUTICS INC - MEANINGFUL REDUCTIONS IN ARRHYTHMIA BURDEN OBSERVED IN FIRST TWO PATIENTS WITH MORE THAN SIX MONTHS OF FOLLOW-UP</p></li><li><p>TENAYA THERAPEUTICS INC: ROBUST TRANSDUCTION AND DEMONSTRATED INCREASES IN PKP2 PROTEIN LEVELS IN FIRST TWO PATIENTS AT WEEK 8</p></li></ul><p>Source text: <span>ID:nGNX8sWwFl</span></p><p>Further company coverage: <span>TNYA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Tenaya Therapeutics says early trial shows promise for gene therapy in rare heart condition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Tenaya Therapeutics says early trial shows promise for gene therapy in rare heart condition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-12 05:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Tenaya <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> says early trial shows promise for gene therapy in rare heart condition </title></head><body><p><span>Dec 11 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/TNYA\">Tenaya Therapeutics Inc</a> <span>TNYA.O</span>:</p><ul><li><p>TENAYA THERAPEUTICS REPORTS POSITIVE INTERIM DATA FROM <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> 1 OF RIDGE™-1 PHASE 1B/2 CLINICAL TRIAL OF TN-401 GENE THERAPY FOR ADULTS WITH PKP2-ASSOCIATED ARVC</p></li><li><p>TENAYA THERAPEUTICS INC - TN-401 WELL TOLERATED AT 3E13 VG/KG DOSE</p></li><li><p>TENAYA THERAPEUTICS INC - MEANINGFUL REDUCTIONS IN ARRHYTHMIA BURDEN OBSERVED IN FIRST TWO PATIENTS WITH MORE THAN SIX MONTHS OF FOLLOW-UP</p></li><li><p>TENAYA THERAPEUTICS INC: ROBUST TRANSDUCTION AND DEMONSTRATED INCREASES IN PKP2 PROTEIN LEVELS IN FIRST TWO PATIENTS AT WEEK 8</p></li></ul><p>Source text: <span>ID:nGNX8sWwFl</span></p><p>Further company coverage: <span>TNYA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA542KXW:1","article_id":"2590491445","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590491445","pubTimestamp":1765487138,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Tenaya Therapeutics says early trial shows promise for gene therapy in rare heart condition Dec 11 (Reuters) - Tenaya Therapeutics Inc TNYA.O:TENAYA THERAPEUTICS REPORTS POSITIVE INTERIM DATA FR","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","TNYA":"Tenaya Therapeutics Inc"},"translate_title":"简介-Tenaya Therapeutics表示，早期试验显示基因治疗罕见心脏病的前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNYA":0.9},"content_text":"BRIEF-Tenaya Therapeutics says early trial shows promise for gene therapy in rare heart condition Dec 11 (Reuters) - Tenaya Therapeutics Inc TNYA.O:TENAYA THERAPEUTICS REPORTS POSITIVE INTERIM DATA FROM COHORT 1 OF RIDGE™-1 PHASE 1B/2 CLINICAL TRIAL OF TN-401 GENE THERAPY FOR ADULTS WITH PKP2-ASSOCIATED ARVCTENAYA THERAPEUTICS INC - TN-401 WELL TOLERATED AT 3E13 VG/KG DOSETENAYA THERAPEUTICS INC - MEANINGFUL REDUCTIONS IN ARRHYTHMIA BURDEN OBSERVED IN FIRST TWO PATIENTS WITH MORE THAN SIX MONTHS OF FOLLOW-UPTENAYA THERAPEUTICS INC: ROBUST TRANSDUCTION AND DEMONSTRATED INCREASES IN PKP2 PROTEIN LEVELS IN FIRST TWO PATIENTS AT WEEK 8Source text: ID:nGNX8sWwFlFurther company coverage: TNYA.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590491445","isCrawlerRequest":true}